Liberum appointed Nomad and Sole Corporate Broker to Futura Medical
Liberum is pleased to announce its appointment as Nomad and Sole Broker to Futura Medical plc.
Futura Medical is a pharmaceutical company with a pipeline of transdermal delivery products in late stage development. The company’s lead product is MED2005, a topical treatment for erectile dysfunction currently in Phase 3 clinical trial. The company was founded in 1997 and was admitted to trading on AIM in 2003.
Liberum has been appointed as Nomad and Sole Broker with immediate effect.
Board – David Parsons
Investment Banking – Bidhi Bhoma, Euan Brown, Kane Collings
Research – Graham Doyle, Alistair Campbell
Sales – Lisa Tugwell, Oliver Baxendale, Julian Collett
Corporate and Investor Relations – Natalie Clarke